Management of optic neuritis and multiple sclerosis

Current Opinion in Ophthalmology

Volumn 12, Issue 6, 2001, Pages 400-407

  Van Stavern, Gregory P ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BETA1A INTERFERON; CORTICOSTEROID; CORTICOTROPIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; GADOLINIUM; GLATIRAMER; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INTERFERON BETA SERINE; METHYLPREDNISOLONE; MITOXANTRONE; PREDNISONE;

CARDIOTOXICITY; CLINICAL TRIAL; HUMAN; IMMUNOMODULATION; IMMUNOPATHOLOGY; MULTIPLE SCLEROSIS; NEUROIMMUNOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NERVE DISEASE; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; REVIEW; STEROID THERAPY; VISION;

HUMANS; MULTIPLE SCLEROSIS; OPTIC NEURITIS; VISION DISORDERS;

EID: 0035208255     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/00055735-200112000-00004     Document Type: Review

References (49)

1. A randomized, controlled trial of corticosteroids in acute optic neuritis
2. Multiple sclerosis
3. Risk factors for developing multiple sclerosis after childhood optic neuritis
4. Visual function five years after optic neuritis: Experience of the Optic Neuritis Treatment Trial
5. Risk of developing multiple sclerosis after uncomplicated optic neuritis: A long-term prospective study
6. A reassessment of the risk of multiple sclerosis developing in patients with optic neuritis after extended follow-up
7. Magnetization transfer imaging in patients with clinically isolated syndromes suggestive of multiple sclerosis
8. Prognostic value of MR and magnetization transfer imaging in patients with clinically isolated syndromes suggestive of multiple sclerosis at presentation
9. Multiple sclerosis-from probable to definite diagnosis: A 7-year prospective study
10. The prognostic value of brain MRI in clinically isolated syndromes of the CNS: A 10-year follow-up
11. The longstanding MS lesion: A quantitative MRI and electron microscopic study
12. Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis
13. Assessing the risk of early multiple sclerosis in patients with clinically isolated syndromes: The role of a follow-up MRI
14. Practice parameter: The role of corticosteroids in the management of acute monosymptomatic optic neuritis
15. Treatment of retrobulbar neuritis with corticotrophin
16. A trial of corticotrophin gelatin injection in acute optic neuritis
17. Effects of intravenous methylprednisolone on outcome in MRI-based prognostic subgroups on acute optic neuritis
18. A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis
19. Steroids for multiple sclerosis and optic neuritis: A meta-analysis of randomized controlled clinical trials
20. Treatment of multiple sclerosis: Recent trials and future perspectives
21. Gastric tolerance of high-dose oral prednisone in multiple sclerosis
22. The Tubingen study on optic neuritis treatment: A prospective randomized and controlled trial
23. Promotion of remyelination by polyclonal immunoglobulin and IVIG in Theiler's virus-induced demyelination and in MS
24. A quantitative study on the fate of the oligodendrocyte in multiple sclerosis lesions: A study of 113 cases
25. Improved vision after intravenous immunoglobulin in stable demyelinating optic neuritis
26. A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis
27. The natural history of multiple sclerosis: A geographically based study. I. Clinical course and disability
28. The natural history of multiple sclerosis: A geographically based study. II. Predictive value of the early clinical course
29. Why treat early multiple sclerosis patients?
30. Diversity and plasticity of self-recognition during the development of multiple sclerosis
31. To treat or not to treat: The therapeutic dilemma of idiopathic monosymptomatic demyelinating syndromes
32. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis
33. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double blind, placebo controlled trial
34. Randomized double-blind placebo-controlled study of interferon beta-1a in relapsing-remitting multiple sclerosis
35. Copolymer I reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double blind, placebo-controlled trial
36. Mitoxantrone in progressive multiple sclerosis: A placebo-controlled, randomized, observer-blind phase III trial: Clinical results and three year follow-up
37. Brain atrophy in relapsing multiple sclerosis: Relationship to relapses, EDSS, and treatment with interferon-beta1a
38. PRISMS-4: Long term efficacy of interferon-B1a in relapsing MS
39. A longitudinal study of brain atrophy in relapsing multiple sclerosis
40. Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta1a or IFN beta1b
41. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis
42. Effect of early interferon treatment on conversion to definite multiple sclerosis: A randomized study
43. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years
44. A prospective, open-label treatment trial to compare the effect of IFN B-1a (Avonex), IFN B1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis
45. Placebo-controlled multicentre randomized trial of interferon B1b in treatment of secondary progressive MS
46. Randomized controlled trial of interferon-B1a in secondary progressive MS
47. What is new in the treatment of multiple sclerosis?
48. Therapy of relapsing multiple sclerosis: Treatment approaches for nonresponders
49. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelineting disease